Puma Biotechnology Inc (PBYI) Given Average Rating of “Hold” by Analysts
Puma Biotechnology Inc (NYSE:PBYI) has been assigned a consensus rating of “Hold” from the eight ratings firms that are currently covering the firm. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $70.50.
A number of research firms recently weighed in on PBYI. Citigroup Inc reaffirmed a “buy” rating and issued a $88.00 price target on shares of Puma Biotechnology in a report on Saturday, March 4th. Royal Bank of Canada reissued a “sector perform” rating and set a $48.00 target price (down previously from $57.00) on shares of Puma Biotechnology in a report on Friday, March 3rd. Credit Suisse Group AG reissued an “outperform” rating on shares of Puma Biotechnology in a report on Wednesday, January 18th. Zacks Investment Research cut Puma Biotechnology from a “buy” rating to a “hold” rating in a report on Tuesday, January 10th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $88.00 target price on shares of Puma Biotechnology in a report on Wednesday, November 30th.
Puma Biotechnology (NYSE:PBYI) opened at 44.45 on Tuesday. The company’s 50-day moving average price is $36.87 and its 200-day moving average price is $43.70. The stock’s market cap is $1.64 billion. Puma Biotechnology has a 12-month low of $19.74 and a 12-month high of $73.27.
Puma Biotechnology (NYSE:PBYI) last released its quarterly earnings results on Wednesday, March 1st. The biopharmaceutical company reported ($2.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.92) by $0.12. On average, equities analysts expect that Puma Biotechnology will post ($8.32) EPS for the current fiscal year.
Your IP Address:
In other Puma Biotechnology news, SVP Richard Paul Bryce sold 2,293 shares of the stock in a transaction that occurred on Friday, January 20th. The stock was sold at an average price of $33.24, for a total transaction of $76,219.32. Following the completion of the transaction, the senior vice president now owns 29,237 shares of the company’s stock, valued at $971,837.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Robert Charnas sold 3,008 shares of the stock in a transaction that occurred on Wednesday, February 1st. The shares were sold at an average price of $31.83, for a total value of $95,744.64. Following the transaction, the insider now directly owns 28,461 shares of the company’s stock, valued at approximately $905,913.63. The disclosure for this sale can be found here. Insiders have sold 15,503 shares of company stock valued at $511,078 in the last three months. Insiders own 22.70% of the company’s stock.
Several institutional investors have recently made changes to their positions in the stock. Tower Research Capital LLC TRC boosted its position in shares of Puma Biotechnology by 253.3% in the third quarter. Tower Research Capital LLC TRC now owns 2,427 shares of the biopharmaceutical company’s stock worth $163,000 after buying an additional 1,740 shares during the last quarter. Ardsley Advisory Partners purchased a new position in shares of Puma Biotechnology during the third quarter worth approximately $201,000. Laurion Capital Management LP purchased a new position in shares of Puma Biotechnology during the third quarter worth approximately $208,000. SG Americas Securities LLC purchased a new position in shares of Puma Biotechnology during the third quarter worth approximately $257,000. Finally, Rothschild Asset Management Inc. purchased a new position in shares of Puma Biotechnology during the third quarter worth approximately $291,000. 80.98% of the stock is owned by institutional investors and hedge funds.
Puma Biotechnology Company Profile
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is developing for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of patients with advanced cancer, and PB357, which is an orally administered agent.
Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.